Henry Schein, Inc. (NASDAQ:HSIC) was the recipient of some unusual options trading activity on Thursday. Investors purchased 3,245 call options on the stock. This represents an increase of 680% compared to the average daily volume of 416 call options.
In other Henry Schein news, Vice Chairman James P. Breslawski sold 6,636 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $61.32, for a total value of $406,919.52. Following the completion of the transaction, the insider now directly owns 265,282 shares in the company, valued at approximately $16,267,092.24. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 1.06% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of HSIC. NEXT Financial Group Inc lifted its position in Henry Schein by 67.3% during the fourth quarter. NEXT Financial Group Inc now owns 378 shares of the company’s stock valued at $25,000 after purchasing an additional 152 shares during the last quarter. Cullen Frost Bankers Inc. lifted its holdings in shares of Henry Schein by 153.1% in the 4th quarter. Cullen Frost Bankers Inc. now owns 496 shares of the company’s stock worth $33,000 after acquiring an additional 300 shares during the last quarter. Parallel Advisors LLC lifted its holdings in shares of Henry Schein by 50.3% in the 4th quarter. Parallel Advisors LLC now owns 923 shares of the company’s stock worth $61,000 after acquiring an additional 309 shares during the last quarter. Meeder Asset Management Inc. lifted its holdings in shares of Henry Schein by 33.2% in the 4th quarter. Meeder Asset Management Inc. now owns 1,123 shares of the company’s stock worth $75,000 after acquiring an additional 280 shares during the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its holdings in shares of Henry Schein by 167.0% in the 4th quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 1,335 shares of the company’s stock worth $89,000 after acquiring an additional 835 shares during the last quarter.
Shares of HSIC traded up $6.45 during trading hours on Thursday, hitting $56.48. 405,521 shares of the stock were exchanged, compared to its average volume of 2,476,093. Henry Schein has a fifty-two week low of $41.85 and a fifty-two week high of $73.99. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.58 and a quick ratio of 0.88. The business has a 50-day moving average of $61.49 and a 200-day moving average of $65.09. The firm has a market capitalization of $6.74 billion, a P/E ratio of 11.95, a price-to-earnings-growth ratio of 1.71 and a beta of 0.92.
Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Thursday, February 20th. The company reported $0.97 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.91 by $0.06. Henry Schein had a net margin of 6.96% and a return on equity of 15.01%. The company had revenue of $2.67 billion during the quarter, compared to analysts’ expectations of $2.64 billion. During the same period in the prior year, the company posted $1.12 earnings per share. Henry Schein’s revenue for the quarter was up 7.9% compared to the same quarter last year. As a group, analysts forecast that Henry Schein will post 3.67 earnings per share for the current fiscal year.
HSIC has been the subject of several recent research reports. BidaskClub cut shares of Henry Schein from a “buy” rating to a “hold” rating in a research report on Saturday, March 21st. Bank of America cut shares of Henry Schein from a “neutral” rating to an “underperform” rating and set a $65.00 price target for the company. in a research report on Thursday, January 9th. ValuEngine cut shares of Henry Schein from a “sell” rating to a “strong sell” rating in a research report on Monday, February 10th. Robert W. Baird cut shares of Henry Schein from an “outperform” rating to a “neutral” rating in a research report on Thursday, January 2nd. Finally, JPMorgan Chase & Co. increased their price objective on shares of Henry Schein from $66.00 to $68.00 and gave the stock a “neutral” rating in a research report on Monday, February 24th. Five equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $70.67.
About Henry Schein
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Featured Story: What is a Market Correction?
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.